AllSci News
USC wins NIA funding to advance first brain-penetrant cPLA2 inhibitors for Alzheimer's
University of Southern California has received a USD 1.67 million NIA U01 cooperative agreement to advance brain-penetrant small molecule inhibitors of...
Weill Cornell advances mitochondrial ROS inhibitors for Alzheimer's with NIA grant
Weill Cornell Medicine has received a USD 4.2 million RF1 grant from the National Institute on Aging (NIA) to advance preclinical development of a class of...
RevaGenix lands USD 12.1m NIAID contract to advance AMR therapeutics
San Mateo, California-based RevaGenix, Inc. has received a USD 12.1 million NIAID R&D contract to advance therapeutic candidates targeting antimicrobial...
University of Washington secures NIH funding for AI-guided islet cell engineering
University of Washington has received a USD 1.71 million NIDDK RC2 grant to develop AI-designed mini-proteins that epigenetically direct pluripotent stem...
UC Davis advances bacterial-made microRNA therapy with renewed NCI funding
University of California, Davis has received a USD 1.18 million National Cancer Institute R01 renewal to advance bioengineered microRNA therapeutics for...
Chugai signs up for Phylo's Biomni Lab agentic AI drug discovery platform
Phylo, Inc. has announced a collaboration with Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4519) to deploy Biomni Lab, Phylo's agentic AI...
IQVIA to support Medera's cardiac gene therapy and human organoid platform
IQVIA (NYSE: IQV) and Medera Inc. have announced a collaboration to advance Medera's cardiac gene therapy pipeline and its Novoheart human cardiac organoid...
Grace Therapeutics raises USD 10m to fund manufacturing strategy for NDA resubmission
Princeton, New Jersey-based Grace Therapeutics, Inc. (Nasdaq: GRCE) announced a USD 10 million private placement to fund manufacturing and regulatory work...
Forlong moves SC IL-15 superagonist into Phase I in Australia
China-based Forlong Biotechnology has announced approval to initiate a Phase I clinical trial of FL115, an IL-15/IL-15Rα-Fbody fusion protein, administered...
Moderna advances Bundibugyo Ebola mRNA vaccine into Phase I
Moderna (Nasdaq: MRNA) has dosed the first participants in a Phase I trial of mRNA-1469, its investigational mRNA vaccine against Bundibugyo ebolavirus...
Arrowhead nabs FDA priority review voucher for plozasiran
Pasadena, California-based Arrowhead Pharmaceuticals (Nasdaq: ARWR) announced that it has signed an agreement to acquire a US FDA Rare Pediatric Disease...
Merck Q2'26: Sac-TMT Phase III win prompts rethink of first-line NSCLC strategy
Merck & Co. (NYSE: MRK) held its Q2 2026 earnings call on August 4, 2026, during which the company reported its first positive Phase III readout from the...
Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook
Pfizer (NYSE: PFE) held its Q2 2026 earnings call on August 4, 2026, with three pipeline developments dominating analyst attention: a Q4 readout for the...
Takeda Q1 FY2026: Zasocitinib, TAK-928 and mezagitamab drive pipeline update
Takeda Q1 2026 Earnings Call on July 30, 2026 revealed that zasocitinib has now demonstrated statistical superiority over deucravacitinib (Sotyktu) across...
UNC Charlotte spinout OncoTab wins grant to advance tMUC1 TCE for pancreatic cancer
OncoTab, a Charlotte, North Carolina-based biotechnology company, has received a USD 1.13 million National Cancer Institute R44 SBIR Phase II grant to...
The AllSci Brief
Free, systematic R&D and deal news. Daily.